1st Quarter - Report

SANOFI US SERVICES INC. for SANOFI US SERVICES INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$1,210,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 18, 2008 $1,210,000 Replaced
1st Quarter - Amendment Dec 18, 2008 $1,190,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S. 1145 "The Patent Reform Act of 2007". All provisions.

Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.

LobbyistCovered position, as disclosed
EDDIE D EVANS —
EDWARD GREISSING —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); White House Office; SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 1145 (110th)

Environment/Superfund ENV

pharmaceuticals in the environment

Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: White House Office; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Provisions related to the extension of the US R&D tax credit in HR1712 "Research and Development Tax Credit Act of 2007" and HR2138 "Investment in America Act of 2007"

Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.

LobbyistCovered position, as disclosed
ANN TAYLOR —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office

Bills named: H.R. 1712 (110th), H.R. 2138 (110th)

Health Issues HCR

Deep Vein Thrombosis awareness; issues related to follow-on biologics included all related provisions in HR 1956 "Patient Protection and Innovative Biologic Medicines Act of 2007", and S 1695 "Biologics Price Competition and Innovation Act of 2007"; comparative effectiveness; the Together Rx Access program; HR 1585 and S567, "National Defense Authorization Act for FY2008"; HR 3222 and HR 2764, "Department of Defense Appropriations Act, 2008", and HR4986, "National Defense Authorization Act for Fiscal Year 2008": provisions related to procurement and reimbursement for services by the TRICARE system and the quality of healthcare delivered by the Defense Health System

Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.

LobbyistCovered position, as disclosed
TIMOTHY CLARK —
EDWARD GREISSING —
RICHARD M HODGE —
SAIRA SULTAN —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); White House Office; SENATE

Bills named: H.R. 4986 (110th), H.R. 1585 (110th), H.R. 1956 (110th), H.R. 3222 (110th), H.R. 2764 (110th)

Medicare/Medicaid MMM

compendia coverage of Medicare Part B drugs, including such related provisions in HR 3162 "Children's Health and Medicare Protection Act of 2007"; Deep Vein Thrombosis issues related to Medicare Part A Regulation and the Medicare Part D Call Letter.

Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.

LobbyistCovered position, as disclosed
MARK COIN —
SAIRA SULTAN —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3162 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.